Immuno-Oncology | Specialty

Investigational Approaches in RCC

March 26th 2015

VEGF Versus mTOR in Non-Clear Cell RCC

March 26th 2015

Sunitinib Versus Pazopanib in Renal Cell Carcinoma

March 26th 2015

Managing Untreated Metastatic Renal Cell Carcinoma

March 26th 2015

Role of Radiation Therapy in Renal Cell Carcinoma

March 26th 2015

Introduction: Surgical Approaches in mRCC

March 26th 2015

Frontline Pembrolizumab Bests Ipilimumab in Phase III Melanoma Trial

March 25th 2015

A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints

Anti-PD-1 Therapy Poised to Take the Next Step in Melanoma

March 25th 2015

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

Hope Rises for Immunotherapy in Breast Cancer

March 25th 2015

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

Prostate Cancer: Which Guidelines

March 19th 2015

Changes in NCCN Guideline: Affecting First-Line

March 19th 2015

Considerations in Treatment Selection

March 19th 2015

Sipuleucel-T: Evidence-based Use

March 19th 2015

Changes in NCCN Guideline: Affecting Second-Line

March 19th 2015

A Review of Bone-Targeted Therapies

March 19th 2015

Sequencing: Important Question With Many Answers

March 19th 2015

Abiraterone: Approval and Use

March 19th 2015

MAINSAIL: Lessons Learned

March 19th 2015

Looking Forward: Immunotherapy and Genomics

March 19th 2015

When to Image: Earlier?

March 19th 2015